Nonalcoholic fatty liver disease (NAFLD) is being increasingly ... Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...

(Reuters) -A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool ...

About 20% of people in Sweden and 25% worldwide may have fatty liver disease, known as MASLD. This condition is linked to ...

A comprehensive study from Karolinska Institutet shows that people with fatty liver disease have almost twice the mortality ...

Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and ...

A comprehensive study shows that people with fatty liver disease have almost twice the mortality rate of the general population. They have an increased risk of dying from both liver diseases and ...

For the first time, the European Medicines Agency has recognized AI software for the diagnosis of fatty liver hepatitis as ...

Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...

A new study has discovered that a special kind of dietary starch — called resistant starch — could play a powerful role in ...